Navigation Links
WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC
Date:3/29/2017

SHANGHAI, March 29, 2017 /PRNewswire/ -- WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec Affiliate, today announced that it had received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm.

Asia-Pacific Bioprocessing Excellence Awards aims to recognize outstanding leaders and trend-setters of today, and inspire innovators of tomorrow. Featuring top bioprocessing and biomanufacturing experts in the industry, along with the latest advances in technologies and best practices in manufacturing, WuXi Biologics has been recognized for its outstanding performance that facilitating biomanufacturing excellence at enhanced speed, reduced cost and superior quality.

As an open-access biologics technology platform, WuXi Biologics opened its state-of-the-art biologics manufacturing facilities at Wuxi city in 2012, which is the first in China that met cGMP standards of the United States, the European Union, and China. In 2015, WuXi began construction of world's largest mammalian cell culture manufacturing facility using disposable bioreactors with a planned manufacturing capacity of 30000L, and completed construction of Asia's largest perfusion biologics manufacturing facility using disposable bioreactors in 2016, offering end-to-end solution to our worldwide customers and partners.

"WuXi Biologics is honored to be recognized by IMAPAC," said Dr. Chris Chen, CEO of WuXi Biologics, "The award truly reflects all of the efforts we have put forth to provide our customers with high-quality and best-in-class service to help accelerate biologics development from concept to commercialization."

About WuXi AppTec

WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."  Please visit http://www.wuxiapptec.com

About WuXi Biologics

WuXi Biologics, a WuXi AppTec Affiliate, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi's Biologics services, please visit:http://www.wuxibiologics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-biologics-receives-asia-pacific-best-bioprocessing-excellence-award-from-imapac-300431576.html


'/>"/>
SOURCE WuXi AppTec
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Research Reports Initiation on Biotech Stocks -- Sangamo, Eyegate Pharma, Synthetic Biologics, and Regulus
2. FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review
3. Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017
4. Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference
5. U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocons Proposed Biosimilar Trastuzumab
6. Genedata Partners with Crescendo Biologics on Next-generation Immuno-oncology and ADC Programs
7. Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics
8. AGC Signs Agreement for Acquisition of Leading Biopharmaceutical CDMO, CMC Biologics
9. FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
10. Innovent Biologics, Inc. Raises USD $260M in Series D Financing
11. WuXi Biologics and Prima Signs MOU and Announces Strategic Development and Manufacturing Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... October 10, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the BoxWorks conference in San Francisco. , The presentation, “Automating GxP ...
(Date:10/9/2017)... ... 2017 , ... The Giving Tree Wellness Center announces the ... of consumers who are incorporating medical marijuana into their wellness and health regimens. ... operators of two successful Valley dispensaries, The Giving Tree’s two founders, Lilach Mazor ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology:
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... UBM,s Advanced Design and Manufacturing event in ... and evolving technology through its 3D Printing and Smart ... the expo portion of the event and feature a ... on trending topics within 3D printing and smart manufacturing. ... will take place June 13-15, 2017 at the Jacob K. ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):